Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 389304 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
ElectronicAdd to Basket
Hard CopyAdd to Basket



Cancer Drug Discoveries: What the Future Holds: Renal Cancer Chapter
Espicom Business Intelligence Ltd, May 2007, Pages: 104


  Description  
  Table of Contents  
  Summary  
    
    
   
 Enquire before Buying  
 Send to a Friend  

The renal cell carcinoma (RCC) market was estimated to be worth around US$1 billion in 2006, with a growth rate of 36% YoY. It has constituted a relatively small segment of the oncology market but has more recently attracted considerable research and development investment from big pharmaceutical, biotechnology and specialty pharma companies.

The market is currently driven by the use of the following immunomodulating agents: Schering-Plough’s Intron A (interferon [IFN] alpha-2b), Roche’s Roferon-A (IFN alpha-2a) and Novartis’ Proleukin (aldesleukin); with new market entrants Bayer/Onyx Pharmaceuticals’ Nexavar (sorafenib) and Pfizer’s Sutent (sunitinib) making significant inroads into the market in 2006, their first year of sales.

The launch of more effective targeted agents and greater use of combination therapies instead of monotherapies, with the establishment of existing and new agents as adjuvant therapy in early-stage disease will contribute to the RCC market’s most eventful decade.

There are significant opportunities for effective new products to expand rapidly, as a large percentage of patients are currently not treated with drug therapies and are not cured by surgery alone. These patients are candidates for adjuvant therapy.

We forecast that sales of RCC treatments will increase to US$3 billion by 2009 and over US$6 billion by 2012 due to the launch of up to nine new therapies. The RCC market is in its most exciting phase of evolution!

Key questions answered include:
What are the reasons behind the expected increase in the patient population with RCC?
What impact will the new oral agents have on a market currently dominated by injectables?
Why is only 25% of the global RCC market in Europe?
What are the prospects for GSK’s pazopanib and what revenue contribution might it make in 2012?
What challenges must Novartis overcome with Proleukin and its new product everolimus if it is to maintain market presence?
What factors are limiting Wilex’ Rencarex commercialisation?
CURRENT PRODUCTS EVALUATED AND FORECAST
Intron-A/PEG-Intron (Schering-Plough)
Roferon-A/Pegasys (Roche)
Proleukin (Novartis/Chiron)
Nexavar (Bayer/Onyx Pharmaceuticals)
Sutent (Pfizer)
UP AND COMING PRODUCTS EVALUATED
PHASE III
Avastin (Roche/Genentech/Chugai)
Everolimus (Novartis)
Pazopanib (GSK)
Rencarex (Wilex)
Torisel (Wyeth)
TroVax (Oxford BioMedica/ sanofi-aventis)
Tykerb (GSK)

PHASE II
rIL-21 (Zymogenetics/Novo Nordisk)
Revlimid (Celgene)
Talactoferrin (Agennix)
ABT-510 (Abbott)
AS1411 (Antisoma)


Around 50% of early-stage patients are not cured by surgery and around 80% of patients with advanced disease fail to respond to approved therapies.

The development of novel, targeted therapies as front-line and/or second-line therapies for metastatic disease, may address this issue



Customers who bought this item also bought

Cancer Drug Discoveries: What the Future Holds: Colorectal Cancer Chapter

Cancer Drug Discoveries: What the Future Holds

The Asian Cancer Market Outlook to 2010

Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter

Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities

Cancer Drug Discoveries: What the Future Holds: Renal Cancer Chapter

The Cancer Market Outlook to 2010

Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter



Top of page


   All rights reserved. Copyright 2008 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds